Psychedelic Stocks

2020-11-02 PSW Editor

This dosing study on LSD will be utilized as MindMed prepares for its Phase 2b clinical trial of LSD for anxiety.

2020-11-02 Jeff Nielson

With an industry-leading psychedelic drug R&D portfolio, MindMed has plenty of options to leverage its cash-on-hand to a higher share price.

2020-10-30 PSW Editor

With MindMed's latest financing, total cash reserves now stand at CAD$50.1 million.

2020-10-29 PSW Editor

Field Trip's new psychedelic molecule, FT-104, is showing similar efficacy to psychedelics like psilocybin -- but with shorter duration.

2020-10-29 Jeff Nielson

Markets are tumbling. Where do you want to be positioned AFTER the selloff is over? Psychedelic stocks.

2020-10-28 Jeff Nielson

MAPS' recent economic study revealed huge cost savings from MDMA-assisted therapy to treat PTSD. But that could be just the beginning of the savings.

2020-10-28 PSW Editor

Entheon Biomedical has received conditional approval from the CSE to commence public trading.

2020-10-27 PSW Editor

MDMA-assisted psychotherapy for PTSD is estimated to produce cost savings of $103,200 per patient, over a 30-year treatment horizon.

2020-10-26 PSW Editor

As the new rally in psychedelic stocks progresses, these four companies are currently setting the pace.

2020-10-22 Jeff Nielson

An enormous Crisis. Huge treatment markets. Massive disruption potential. Welcome to the psychedelic drug industry.

2020-10-22 PSW Editor

Field Trip Health opens a new clinic in Chicago, its 4th ketamine-assisted psychotherapy clinic.

2020-10-22 PSW Editor

Numinus announces its first psilocybin harvest and the appointment of a new Science Officer.